16 September 2026 editorial review · Item
GLP-1 drugs to rescue beta cells at diagnosis: review notes
These notes document the scope actually reviewed, including source-access limits. They are not independent clinical certification or a guarantee that every claim was verified.
Read the item evidence page →Preventing and curing evidence review — 16 September 2026
- Disposition: reviewed; no confirmed content change. Current item
lastReviewed: 2026-08-27. - Claim check: The new-onset semaglutide series has ten participants and no comparator. It does not prove beta-cell regeneration or disease modification. Adjunct obesity trials in established T1D do not establish new-onset preservation.
- Registry NCT07614412: NOT_YET_RECRUITING; updated 2026-05-29; enrollment 240 (ESTIMATED); primary completion 2028-01-31 (ESTIMATED); results not posted in retrieved record.
- Primary publication/regulatory sources checked or consulted: NEJMc2302677; 19322968241305641.